11/15
07:35 am
ganx
Gain Therapeutics GAAP EPS of -$0.17 [Seeking Alpha]
Low
Report
Gain Therapeutics GAAP EPS of -$0.17 [Seeking Alpha]
11/14
04:17 pm
ganx
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update [Yahoo! Finance]
11/14
04:05 pm
ganx
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Medium
Report
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
10/23
08:00 am
ganx
Gain Therapeutics Presents Data at 36?? EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
Medium
Report
Gain Therapeutics Presents Data at 36?? EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
10/15
07:00 am
ganx
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/9
08:33 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
10/9
08:30 am
ganx
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
Medium
Report
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
10/7
07:00 am
ganx
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
High
Report
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
10/3
07:00 am
ganx
Gain Therapeutics to Participate at Upcoming Investor Conferences
Medium
Report
Gain Therapeutics to Participate at Upcoming Investor Conferences
10/1
08:01 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/30
07:00 am
ganx
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
High
Report
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
9/26
07:00 am
ganx
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
Low
Report
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
9/19
07:00 am
ganx
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
Neutral
Report
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
9/3
08:04 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/3
07:00 am
ganx
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
8/30
05:43 am
ganx
Gain Therapeutics reports positive data from Phase I Parkinson's treatment trial [Yahoo! Finance]
High
Report
Gain Therapeutics reports positive data from Phase I Parkinson's treatment trial [Yahoo! Finance]
8/29
07:30 am
ganx
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
High
Report
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease